Septerna reports Q3 net income of $8.2M; cash at $561.6M into 2029; SEP-479 candidate selected

Septerna, Inc.

2025-Q3 EPS reported -$0.86 vs consensus $0.81 ▼ miss (-206.2%)

Q3 2025 net income $8.2M vs net loss $20.5M in Q3 2024; revenue $21.5M from Novo Nordisk collaboration.
Cash and equivalents $561.6M, including $195M upfront from Novo Nordisk and $12.5M from Vertex; runway into 2029.
Selected SEP-479 as oral PTH1R agonist development candidate for hypoparathyroidism; Phase 1 expected H1 2026.
SEP-631 Phase 1 ongoing for mast cell diseases; initial data expected H1 2026.
Appointed Keith Gottesdiener, M.D., to Board as chair of R&D Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.